Biological Activity:Elacridar (GF120918; GW0918) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.Target: P-glycoproteinIn vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma. GF120918A did not demonstrate potent inhibition of several human cytochrome P450 enzymes evaluated in vitro, with IC(50) values well above concentrations anticipated to be achieved in vivo. Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclinical species and offer additional guidance on preclinical dose regimens likely to produce P-glycoprotein-mediated effects.Solvent&Solubility: 10 mM in DMSO备注：产品信息可能会有优化升级。请以实际标签信息为准。备注：以上数据均来自公开文献, Solarbio暂未进行独立验证, 仅供参考。These protocols are for reference only. Solarbio does not independently validate these tmethods.